We hypothesise that in this subgroup of MM patients with clinically relevant osteolytic lesions, a high tumour load can be assumed anyway, while the malignant potential is better indicated by CRP as surrogate marker for IL-6 levels. The gene discussed is CRP; the disease is neoplasm.